$XTALPI(02228.HK) To be honest, Jingtai started off by steadily focusing on AI drug development, which was the right path. However, AI drug development has a slow return on investment and a long cycle. Later, the three core scientists deviated from the original goal, no longer deepening the main business, but instead making reckless investments everywhere and expanding across boundaries.

Now it has long since changed its nature, gradually turning into a resource integration investment company. The profits and reputation of many projects are credited to other companies, while it itself has little solid output. The market cap of over 30 billion is completely unsustainable, purely inflated by hype. Fellow naive investors should not blindly follow. The losses are your own money. The Hong Kong stock market is still quite good, with decent returns from applying for an IPO. If you really want to buy, go to the US stock market.